Navigation Links
FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
Date:8/26/2011

d received prior chemotherapy.

In one study, the objective response rate was 50 percent with a median response duration of 42 weeks. In another, the objective response rate was 61 percent with a median response duration of 48 weeks.

The FDA based its approval of the Vysis ALK Break Apart FISH Probe Kit on data from one of the studies.

Xalkori was reviewed under the FDA's priority review program, which provides for an expedited six-month review of drugs that may offer major advances in treatment or that provide a treatment when no adequate therapy exists.

Xalkori is being approved under the FDA's accelerated approval program, which allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients. The program is designed to provide patients with earlier access to promising new drugs, followed by further studies to confirm the drug's clinical benefit.

Xalkori and the companion Vysis ALK Break Apart FISH Probe Kit were approved ahead of the drug's Sept. 30, 2011, FDA review goal date and the companion diagnostics' Sept. 28, 2011, review goal date. 

"The trend in oncology research continues towards targeted therapies," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health. "This test is an example of the important role companion diagnostics play in determining that the safest and most effective treatments are promptly delivered to patients living with serious and life-threatening diseases."

The most common side effects reported in patients receiving Xalkori included vision disorders, nausea, diarrhea, vomiting, swelling (edema), and constipation. Vision disorders included visual impairment, flashes of light, blurred vision, floaters, double vision, sensitivity to light, and
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
2. FDA Approves Adcetris to Treat Two Types of Lymphoma
3. FDA Approves the First Specific Treatment for Scorpion Stings
4. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
5. FDA Tentatively Approves Intellijects Lead Product, e-cue™
6. FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US
7. FDA Approves Vaccines for the 2011-2012 Influenza Season
8. FDA Approves Boostrix to Prevent Tetanus, Diphtheria, and Pertussis in Older People
9. FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
10. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
11. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Treated Using Next Generation CyberKnife System at Oklahoma ... ... ARAY ), a global leader in the field of radiosurgery,announced ... Robotic Radiosurgery System that was recently,installed at the Oklahoma CyberKnife, LLC ...
... Explore the Effects of Eligen(R) Delivery Technology and ... in Postmenopausal Women, CEDAR KNOLLS, N.J., Aug. ... announced today that Novartis Pharma AG,has finished recruitment ... and efficacy of Salmon Calcitonin and Emisphere,s proprietary,Eligen(R) ...
Cached Medicine Technology:New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... CAMBRIDGE, Mass., March 11 Idenix,Pharmaceuticals, Inc. (Nasdaq: ... corporate overview at the upcoming Eleventh Annual Lehman,Brothers Global ... ET at the Loews Miami Beach Hotel in South ... the company presentation can be,accessed under "Calendar of Events" ...
... also increases odds, study finds , , TUESDAY, March ... for glaucoma and those with high pressure in their ... a new study suggests. , "Glaucoma is one of ... from Stony Brook University in Stony Brook, N.Y., wrote ...
... help, at least for a while, study finds, , , TUESDAY, ... are often dismal, but a new study finds that when ... able to keep off more weight. , The study ... more likely to maintain their weight loss than people who ...
... SAN DIEGO, March 11 Dr. Fred Baughman released ... with you, that "Illness of the brain must be ... of Representatives have,passed a mental health parity bill. The ... diagnoses are actual diseases, disorders or,illnesses of the brain. ...
... time when several U.S. health insurers have discontinued payment ... colonoscopies, physicians at the University of Pennsylvania School of ... the drug could both save millions of health care ... pain relief. , The researchers studied two groups of ...
... Women with Knowledge and Tools for ... Lifelong Sobriety, CENTER ... a new addiction recovery resource for women,A Woman,s Guide to Recovery. Written ... offers an honest and direct,approach for women seeking solace from the grips ...
Cached Medicine News:Health News:Glaucoma May Boost Cardiovascular Death Risk in Blacks 2Health News:Personal Contact Helps Maintain Weight Loss 2Health News:Personal Contact Helps Maintain Weight Loss 3Health News:Open Letter to Speaker Pelosi on Approval of Mental Health Parity 2Health News:Open Letter to Speaker Pelosi on Approval of Mental Health Parity 3Health News:Penn research offers road map to safer pain control, cost savings during colonoscopies 2Health News:Hazelden Publishing Unveils Valuable New Resource for Women Seeking Recovery From Addiction 2Health News:Hazelden Publishing Unveils Valuable New Resource for Women Seeking Recovery From Addiction 3
... protein-2 (IGFBP-2) is one of six characterized ... specifically bind and modulate the actions of ... IGFBP-2 for IGF-II is estimated to be ... a role in regulation of IGF-II action. ...
... heterodimeric proteins that suppress the secretion of ... Inhibin consists of two distinct chains, or ... A consists of the alpha-subunit and betaA-subunit. ... betaB-subunit. Only the dimeric forms of the ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
Medicine Products: